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Research
AbstrACt
Objective This study aims: (1) to describe the pattern 
and extent of multimorbidity and polypharmacy in UK 
Biobank participants with chronic obstructive pulmonary 
disease (COPD) and (2) to identify which comorbidities are 
associated with increased risk of adverse drug reactions 
(ADRs) resulting from polypharmacy.
Design Cross-sectional.
setting Community cohort.
Participants UK Biobank participants comparing self-
reported COPD (n=8317) with no COPD (n=494 323).
Outcomes Multimorbidity (≥4 conditions) and 
polypharmacy (≥5 medications) in participants with COPD 
versus those without. Risk of ADRs (taking ≥3 medications 
associated with falls, constipation, urinary retention, 
central nervous system (CNS) depression, bleeding or renal 
injury) in relation to the presence of COPD and individual 
comorbidities.
results Multimorbidity was more common in participants 
with COPD than those without (17% vs 4%). Polypharmacy 
was highly prevalent (52% with COPD taking ≥5 
medications vs 18% in those without COPD). Adjusting 
for age, sex and socioeconomic status, those with COPD 
were significantly more likely than those without to be 
prescribed ≥3 medications contributing to falls (OR 2.27, 
95% CI 2.13 to 2.42), constipation (OR 3.42, 95% CI 3.10 
to 3.77), urinary retention (OR 3.38, 95% CI 2.94 to 3.87), 
CNS depression (OR 3.75, 95% CI 3.31 to 4.25), bleeding 
(OR 4.61, 95% CI 3.35 to 6.19) and renal injury (OR 
2.22, 95% CI 1.86 to 2.62). Concomitant cardiovascular 
disease was associated with the greatest risk of taking ≥3 
medications associated with falls/renal injury. Concomitant 
mental health conditions were most strongly associated 
with medications linked with CNS depression/urinary 
retention/bleeding.
Conclusions Multimorbidity is common in COPD 
and associated with high levels of polypharmacy. Co-
prescription of drugs with various ADRs is common. 
Future research should examine the effects on healthcare 
outcomes of co-prescribing multiple drugs with similar 
potential ADRs. Clinical guidelines should emphasise 
assessment of multimorbidity and ADR risk.
bACkgrOunD
In people with chronic obstructive pulmo-
nary disease (COPD), multimorbidity (the 
presence of ≥2 long-term conditions (LTCs)) 
is highly prevalent.1–4 A recent meta-anal-
ysis of 29 datasets demonstrated that those 
with COPD are significantly more likely to 
be diagnosed with a range of cardiovascular 
comorbidities than those without COPD (we 
will use the term comorbidity when referring 
to specific conditions in addition to COPD 
and multimorbidity to refer to the pres-
ence of ≥2 LTCs).5 Other LTCs with known 
increased prevalence in COPD include 
obesity,6 depression,7–10 gastro-oesophageal 
reflux disease,11–13 osteoporosis14–16 and lung 
cancer.17 18 Each of these conditions has 
been associated with poorer health-related 
outcomes in COPD when compared with 
those with no comorbidity.19–30 The overall 
burden of multimorbidity also impacts 
strengths and limitations of this study
 ► This paper assesses multimorbidity, polypharmacy 
and risk of adverse drug reactions  (ADRs) in UK 
Biobank participants with self-reported chronic 
obstructive pulmonary disease (COPD) compared 
with those without COPD.
 ► Baseline variables from the UK Biobank assessment 
centre were used to adjust for potential confounders.
 ► Cumulative risk of common ADRs was quantified 
by identifying UK Biobank participants taking 
≥3 medications associated with similar ADRs.
 ► Analyses were repeated using a subgroup of 
participants with spirometry data confirming airflow 
obstruction.
 ► Medication and comorbidity data rely on participant 
self-report and may thus be susceptible to bias or 
inaccuracy.
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prognosis in COPD, for example higher number of 
comorbidities is associated with higher risk of mortality,31 
and higher burden of morbidity assessed using the 
Charlson index and the COPD-specific comorbidity test 
is associated with higher risk of all-cause and respirato-
ry-specific mortality.32 33 The importance of considering 
the impact of multimorbidity in the management of LTCs 
is increasingly recognised, particularly in the context of 
an ageing society in which the prevalence of multimor-
bidity is growing.34 However, an immature evidence base 
means that disease-specific guidelines often lack specific 
recommendations with respect to multimorbidity.35 The 
prevalence and prognostic significance of multimorbidity 
in COPD make it a potentially useful exemplar condition 
in which to consider the specific implications of different 
patterns of multimorbidity. Polypharmacy is one such 
implication.
Multimorbidity in the general population is associated 
with polypharmacy (often defined as concomitant use of 
≥5 or ≥10 pharmacological agents).36 Polypharmacy has 
been associated with increased risk of adverse drug reac-
tions (ADRs)37–39 and potentially preventable hospital 
admissions, particularly in the elderly.40 41 This is partic-
ularly pertinent in an ageing society, in which a rising 
prevalence of polypharmacy has been observed.34 37 It has 
been demonstrated that diagnosis of COPD is associated 
with increased risk of polypharmacy.42 43 This is, in large 
measure, due to the high burden of extrapulmonary 
comorbidities.44 However, little is known about the risk of 
ADRs in the context of multimorbidity in COPD.
Given the well-established burden of multimorbidity 
and polypharmacy in COPD, it is likely that those with 
COPD are at increased risk of ADRs resulting from poly-
pharmacy. Previous analyses have not focused on the risk 
of specific ADRs, or assessed which LTCs increase this 
risk, instead reporting overall counts of prescribed medi-
cation. Data collected for the UK Biobank cohort offers 
an opportunity to assess how multimorbidity in COPD 
relates to polypharmacy and to assess the prevalence of 
co-prescription of medications with similar ADRs.
This paper aims:
 ► to describe the pattern and extent of multimorbidity 
and polypharmacy in UK Biobank participants with 
COPD;
 ► to identify which LTCs in people with COPD are asso-




The UK Biobank is a large, population cohort that 
recruited voluntary participants from throughout the UK. 
Between 2006 and 2010, UK Biobank recruited 502 640 
participants aged 37–73. Participants underwent baseline 
assessments at one of 22 assessment centres throughout 
England, Scotland and Wales. Sociodemographic and life-
style details were recorded using touchscreen question-
naires. Townsend scores were derived from participant 
postcodes to provide an area-based measure of socioeco-
nomic deprivation. Self-reported LTCs, prescribed and 
over-the-counter medications, smoking status (current, 
previous or never) and frequency of alcohol intake 
(never/special occasions only, 1–3 times a month, at least 
once a week) were recorded from a touchscreen ques-
tionnaire and subsequent verbal interview with a study 
nurse. Physical activity was self-reported based on a ques-
tionnaire administered in the UK Biobank assessment 
centre.45 We classified the responses into: none (no phys-
ical activity in the last 4 weeks), low (light ‘ do-it-yourself 
(DIY)’ activity only in the last 4 weeks), medium (heavy 
DIY and/or walking for pleasure and/or other exercises 
in the last 4 weeks) and high (strenuous sports in the last 
4 weeks).
Study centre staff also collected physical measures 
including height and weight (to calculate body mass 
index; BMI) and spirometry. Spirometry was performed 
using a Vitalograph Pneumotrac 6800. Individual reasons 
for contraindications to attempting spirometry were not 
recorded but, according to protocol, these included chest 
infection in the last month, history of collapsed lung and 
heart attack or surgery in the past 3 months. Full details 
of the Biobank spirometry protocol are available at their 
website (https:// biobank. ctsu. ox. ac. uk/ crystal/ docs/ 
Spirometry. pdf). In brief, participants were allowed up 
to three attempts to provide two reproducible spirometry 
measurements. Where the reproducibility of the first two 
was deemed acceptable (<5% variation in both forced 
expiratory volume in  1  s (FEV1) and forced vital capacity 
(FVC)), a third measurement was not performed. All 
values were recorded along with any error messages 
generated. As per the American Thoracic Society/Euro-
pean Respiratory Society (ATS/ERS) end-of-test criteria, 
we interpreted as valid any measurement with no error 
message or if ‘user accepted’ was specified.46 No post-
bronchodilator measurements were recorded, which 
deviates from the ATS/ERS guidelines and the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
guidelines for COPD.47 48
Participants provided full informed consent to partici-
pate in UK Biobank.
Defining COPD
Participants reporting to have been diagnosed with 
COPD, chronic bronchitis or emphysema at the nurse-led 
interview were coded as having ‘self-reported COPD’.
Due to the potential inaccuracies of using self-reported 
diagnoses, we identified a subset of those with self-re-
ported COPD who met an adaptation of the GOLD 
spirometry criteria for COPD.48 This subset, referred to as 
‘GOLD COPD’, was used as a sensitivity analysis for self-re-
ported COPD and to stratify findings by severity of airflow 
obstruction. For participants with self-report COPD and 
valid spirometry measurements, we calculated the ratio 
of FEV1 to FVC using the highest measurement for each 
participant meeting the ATS/ERS end-of-test criteria.46 
Those with a FEV1/FVC ratio <0.7 were classed as having 
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an obstructive deficit and thus meeting the GOLD diag-
nostic criteria for COPD. We used the Hankinson equa-
tion,49 based on recorded age, sex and height, to calculate 
predicted FEV1 values for each participant. Those with 
GOLD COPD were classified on the basis of their best 
available FEV1 measurement as having mild (>80% 
predicted FEV1), moderate (50%–80% predicted FEV1), 
or severe (<50% predicted FEV1) airflow obstruction in 
line with the GOLD COPD guidelines.48
Defining long-term conditions and medications
All LTCs were defined by self-report. The list of included 
LTCs was taken from a list of 42 morbidities originally 
established for a large multimorbidity epidemiological 
study in Scotland, through systematic review, the Quality 
and Outcomes Framework, NHS Scotland and an expert 
panel,34 and subsequently amended for UK Biobank.50 
The inclusion of ‘other painful conditions’ comprised 
LTCs in which pain is a predominant feature (particularly 
as this is likely to influence medication use). It should be 
noted that such a list is not exhaustive, but intended to 
cover common conditions frequently requiring prescrip-
tion of analgesics (eg, osteoarthritis, back pain, head-
aches, etc). Morbidities were categorised for the purposes 
of this analysis into cardiovascular disease, gastrointestinal 
disease, mental health conditions, cancer and painful 
conditions/inflammatory arthropathies (comprising the 
list of ‘other painful conditions’ mentioned above, plus 
connective tissue diseases). Full details of conditions 
comprising each category can be found in online supple-
mentary appendix 1.
Medication data were collected by self-report. Medica-
tions were coded by mechanism of action according to 
the British National Formulary (BNF) (eg, ACE inhibi-
tors, beta-blockers, calcium channel blockers, etc).51 For 
some situations where more than one medication with a 
similar mechanism of action may be commonly co-pre-
scribed (eg, aspirin and clopidogrel, both antiplatelets) 
these were coded separately. A complete list of the medi-
cations coded within each class can be found in online 
supplementary appendix 2.
We defined those at risk of specific ADRs as anyone on 
≥3 medications with similar potential ADRs, based on 
information provided in the Scottish Government Model of 
Care Polypharmacy Working Group: Polypharmacy Guidance.52 
This guideline cross-tabulates commonly prescribed 
medications with common ADRs to help identify those at 
cumulative risk of ADRs. This document groups common 
medications by similar potential ADRs. While this list is 
not all-inclusive, and the cut-off value of ≥3 medications is 
arbitrary, this does allow an estimation of the cumulative 
risk of specific ADRs. We identified six potential ADRs 
(falls/fractures, constipation, urinary retention, central 
nervous system (CNS) depression, bleeding and renal 
injury) for which the proportion of participants taking 
≥3 associated medications could be assessed. It should be 
noted that several of these events (eg, falls/fractures, CNS 
depression) are often multifactorial and medication may 
be a contributing factor rather than a definitive cause. As 
the guideline acknowledges, however, these are clinical 
events of which the risk is increased by taking multiple 
associated medications.
statistical analysis
All analyses were planned prior to inspection of the data.
Baseline variables
Comparisons were made between participants with 
self-reported COPD and the rest of the cohort (who did 
not report COPD). Age, sex, smoking status, deprivation 
(Townsend score), BMI, physical activity and frequency of 
alcohol intake were compared using χ2 test for categorical 
variables, χ2 test for trend for ordinal variables and Mann-
Whitney U test for continuous variables. Total number of 
morbidities, prevalence of specific morbidities, number 
of self-reported prescribed medications and proportion 
of participants taking each class of medication (online 
supplementary appendix 2) were also compared between 
those with self-reported COPD and the rest of the cohort. 
All comparisons were repeated comparing participants 
with GOLD COPD only with those without COPD, strati-
fied by severity of airflow obstruction.
Multimorbidity and polypharmacy
Logistic regression analyses were used to compare partici-
pants with self-reported COPD and those without COPD. 
ORs and 95% CIs were calculated for:
 ► the presence of cardiovascular disease, cancer, gastro-
intestinal disease, mental health conditions and 
painful conditions/inflammatory arthropathies;
 ► the presence of ≥4 morbidities (excluding COPD);
 ► the use of ≥5 and ≥10, medications (two separate 
models).
Models were initially adjusted for age, sex and socio-
economic deprivation (model 1), then adjusted for the 
addition of smoking status, alcohol frequency, BMI and 
physical activity (model 2). These analyses were repeated 
comparing those with GOLD COPD only to those without 
COPD.
risk of ADrs
For each potential ADR (falls/fractures, constipation, 
urinary retention, CNS depression, bleeding and renal 
injury) participants taking ≥3 medications associated with 
that ADR were identified. The following comparisons 
were then made:
 ► Unadjusted percentages at risk of each ADR were 
calculated for participants without COPD, with self-re-
ported COPD and with self-reported COPD plus 
each category of LTC (cardiovascular disease, cancer, 
gastrointestinal disease, mental health conditions 
and painful conditions/inflammatory arthropathies) 
to give an impression of the ADR risk in COPD and 
identify LTCs in those with COPD that may increase 
this risk.
 ► ORs of being at risk of each ADR were calculated 
comparing those with self-reported COPD to those 
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without COPD adjusting for age, sex and socioeco-
nomic deprivation (model 1) and for age, sex, soci-
oeconomic deprivation, smoking status, alcohol 
frequency, BMI and physical activity (model 2).
 ► ORs of being at risk of each ADR were calculated 
comparing those with and without self-reported 
COPD in each LTC category to (ie, participants 
with cardiovascular disease alone compared with 
participants with cardiovascular disease plus COPD, 
etc). This was intended to identify whether specific 
patterns of multimorbidity in COPD are associated 
with increased ADR risk. Adjustment for a wide range 
of potential confounders was not appropriate in these 
models due to the smaller number of participants in 
each model.
Each analysis was repeated comparing GOLD COPD 
only to those without COPD. Less than 3% of participants 
(with or without COPD) had missing data for potential 
confounding variables (table 1). Those with missing data 
were excluded from adjusted analyses. Spirometry data 
were missing for 3591 participants with self-report COPD 
(43%), hence the use of the GOLD COPD subset as a 
sensitivity analysis.
All analyses were performed using R statistical software 
(V.3.3.1).
results
At the time of recruitment, 8317 out of 502 619 partic-
ipants reported having COPD (1.7%) and are referred 
to here as the self-report COPD group. Of those who 
self-reported COPD, 4726 (57%) had valid spirometry 
measurements. Spirometry was contraindicated or not 
available in 2507 of those with self-reported COPD. 
Spirometry measurements did not meet the ATS/ESR 
end-of-test criteria in 1084 participants.46 Of those with 
valid spirometry, 2620 (55%) met the GOLD criteria 
for airflow obstruction (399 (15%) mild, 1409 (54%) 
moderate, 812 (31%) severe, see figure 1) and are 
referred to here as GOLD COPD.
baseline variables
Table 1 describes and compares the characteristics of 
those with and without COPD in UK Biobank. Partic-
ipants with COPD (both self-report and GOLD) were 
significantly older, more socioeconomically deprived 
and less physically active. A higher proportion of those 
with COPD were male, obese and had a history of 
smoking.
Multimorbidity and polypharmacy
Prevalence of each category of comorbidity was higher 
in those with COPD than without (table 2). After 
controlling for age, sex and socioeconomic status, 
those with self-reported COPD were significantly 
more likely than those without to have each category 
of LTC examined: cardiovascular disease (OR 1.45; 
95% CI 1.39 to 1.52), cancer (OR 1.29, 95% CI 1.2 to 
1.39), gastrointestinal disease (OR 1.76, 95% CI 1.67 
to 1.86), mental health conditions (OR 2.02, 95% CI 
1.89 to 2.15) and painful conditions (OR 1.54, 95% CI 
1.46 to 1.62). Results for GOLD COPD also suggested 
higher likelihood of each LTC compared with those 
without COPD, although the ORs were lower and 
results for cancer not statistically significant (online 
supplementary appendix 3). Results were similar after 
adjusting for additional confounders (smoking status, 
alcohol frequency, BMI and physical activity) with the 
exception of cardiovascular disease in GOLD COPD, 
which was no longer significantly associated (OR 1.08, 
95% CI 0.99 to 1.18) (online supplementary appendix 
3).
Morbidity counts (excluding COPD) and counts of 
prescribed medication are shown in table 2 comparing 
those with COPD, stratified by severity of airflow obstruc-
tion, with those without. Those with COPD had higher 
numbers of LTCs and more prescribed medications than 
those without. There was a trend towards more prescribed 
medications in those with greater severity of airway obstruc-
tion. After controlling for age, sex and socioeconomic 
status, those with self-report COPD were more likely to 
report ≥4 LTCs (OR 3.49, 95% CI 3.28 to 3.71), ≥5 medica-
tions (OR 3.85, 95% CI 3.68 to 4.03) and ≥10 medications 
(OR 5.72, 95% CI 5.36 to 6.10) than those without COPD. 
Results were similar for GOLD COPD and remained statis-
tically significant after adjusting for smoking status, alcohol 
frequency, BMI and physical activity (online supplementary 
appendix 3).
ADr risk
Counts and percentages of participants taking specific 
medications are shown in online supplementary appendix 
4. Participants with COPD (self-report and GOLD) were 
more likely that those without COPD to be prescribed 
drugs across a range of disease areas, reflecting the range 
of LTCs present among those with COPD. The percentages 
of participants within each category (no COPD, COPD and 
COPD with specific LTCs) taking ≥3 medications associated 
with a similar ADR is shown in figure 2. For each category 
of ADR a higher proportion of participants with COPD 
reported taking ≥3 associated medications than those 
without COPD. This increased further with multimorbidity. 
Participants with COPD plus cardiovascular disease had 
the highest percentage taking ≥3  medications with a risk 
of falls or renal injury. Participants with COPD plus mental 
health conditions had the highest percentages taking 
≥3 medications with a risk of constipation, CNS depression 
or bleeding.
After adjusting for age, sex and socioeconomic depriva-
tion, those with self-report COPD remained more likely 
to be taking ≥3 medications in each category than those 
without COPD. These findings remained statistically signif-
icant after adjusting for smoking status, alcohol frequency, 
BMI and physical activity (table 3). Findings were similar 
for GOLD COPD however, after adjusting for additional 
potentially confounding variables, results for bleeding risk 
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Table 1 Baseline variables
Characteristic
No COPD, n=494 323 COPD (self-report), n=8317 GOLD COPD, n=2620
Count % Count % P value Count % P value
Sex <0.001 <0.001 
  Male 224 906 45.5 4268 51.3 1426 54.4 
  Female 269 417 54.5 4049 48.7 1194 45.6 
Age <0.001 <0.001 
Median: 58 Median: 62 Median: 63 
IQR: 50–63 IQR: 57–66 IQR: 59–66 
Ethnicity <0.001 <0.001 
  White 464 770 94.5 8052 97.3 2620 100
  Other 26 821 5.4 219 2.6 0 0
  Missing 2732 46 0 0
Socioeconomic deprivation quintile <0.001 <0.001 
  1 (least deprived) 99 672 20.2 1015 12.2 309 11.8 
  2 98 977 20.0 1142 13.7 362 13.8 
  3 99 013 20.1 1399 16.8 440 16.8 
  4 98 660 20.0 1735 20.9 580 22.2 
  5 (most deprived) 98 385 19.7 3015 36.3 926 35.4 
  Missing 616 11 3
Smoking status <0.001 <0.001 
  Current 50 817 10.3 2172 26.3 833 32.2 
  Previous 169 015 34.4 4083 49.5 1398 54.0 
  Never 271 602 55.3 1999 24.2 360 13.9 
  Missing 2889 63 29 
Alcohol frequency <0.001 <0.001 
  Daily 100 070 20.3 1720 20.7 618 23.6 
  3–4 times/week 114 058 23.1 1404 16.9 475 18.2 
  1–2 times/week 127 459 25.9 1863 22.5 561 21.5 
  1–3 times/month 54 979 11.2 894 10.8 289 11.1 
  Occasional 56 707 11.5 1322 15.9 387 14.8 
  Never 39 569 8.0 1092 13.2 284 
  Missing 1481 22 6 10.9 
BMI <0.001 <0.001 
  <18.5 2478 0.5 148 1.8 56 2.2 
  18.5–24.9 155 282 31.8 2185 26.8 829 31.9 
  25.0–29.9 211 102 43.2 3165 38.9 1049 40.4 
  >30 119 813 24.5 2647 32.5 665 25.6 
  Missing 5648 172 21 
Physical activity <0.001 <0.001 
  High 49 827 10.6 250 3.1 70 2.7 
  Medium 387 766 79.6 5838 72.0 1902 73.3 
  Low 18 354 3.8 589 7.3 203 7.8 
  None 31 425 6.4 1433 17.7 421 16.2 
  Missing 6951 207 24 
FEV1 (% predicted) <0.001 <0.001 
  >80 272 109 78.0 1853 39.2 399 15.2 
  50–79 71 727 20.6 2022 42.8 1409 53.8 
Continued
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were not statistically significant in this sensitivity analysis 
(table 3).
Finally, each category of ADR risk was assessed in a 
subgroup analysis for each category of LTC (cardiovas-
cular, GI, cancer, mental health and painful conditions/
inflammatory arthropathies) comparing those with and 
without COPD (eg, participants with cardiovascular 
disease plus COPD compared with participants with 
cardiovascular disease alone, etc). These models were 
adjusted for age, sex and socioeconomic status only. 
Within each category of LTC, those with self-reported 
COPD were more likely to be at risk of each ADR than 
those without COPD (online supplementary appendix 
3). Not all results were statistically significant when 
using GOLD COPD (online supplementary appendix 
3).
DisCussiOn
summary of main findings
Multimorbidity and polypharmacy in COPD were 
common among UK Biobank participants. The presence 
of multimorbidity was highly prevalent in those with 
COPD (85%). More than half (52%) reported polyphar-
macy (≥5 medications) and 15% reported ≥10 medica-
tions. The prevalence of cardiovascular disease, as well 
as the degree of polypharmacy, was higher among those 
with more severe airflow obstruction.
For the first time, our data demonstrate that those 
with COPD were more likely than those without to 
be prescribed multiple medications (≥3) with similar 
ADRs. Those with COPD plus cardiovascular disease 
were most likely to be taking multiple medications asso-
ciated with increased risk of falls or renal injury, while 
Characteristic
No COPD, n=494 323 COPD (self-report), n=8317 GOLD COPD, n=2620
Count % Count % P value Count % P value
  <50 4841 1.4 851 18.0 812 31.0 
  Missing 145 646 3591 1061 
BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1  s; GOLD, Global Initiative 
for Chronic Obstructive Lung Disease.
Table 1 Continued 
Figure 1 Flow diagram of identification of participants with ‘self-report COPD’ and ‘GOLD COPD’. COPD, chronic obstructive 
pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic 
Obstructive Lung Disease. 
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those with COPD plus mental health conditions were 
most likely to be taking medications predisposing to 
constipation, CNS depression and bleeding.52 Within 
each category of LTC, those with COPD were more 
likely to be taking multiple medications with similar 
ADRs than those without. These associations between 

















Total comorbidities (excluding COPD)
  ≥4 19 959 (4.0) 1389 (16.7)** 331 (12.6)** 46 (11.5) 191 (13.5) 94 (11.6) 
Total number of medications 
  ≥1 356 406 (72.1) 7670 (92.2)** 2452 (93.6)** 352 (88.2) 1321 (93.8) 779 (95.9) 
  ≥5 87 286 (17.7) 4312 (51.8)** 1349 (51.5)** 171 (42.9) 702 (49.8) 476 (58.6) 
  ≥10 10 678 (2.2) 1269 (15.3)** 329 (12.6)** 31 (7.8) 172 (12.2) 126 (15.5) 
Prevalence of comorbidities
Cardiovascular 152 891 (30.9) 3957 (47.6)** 1156 (44.1)** 142 (35.6) 611 (43.4) 403 (49.6) 
  Hypertension 130 119 (26.3) 3206 (38.5)** 916 (35.0)** 112 (28.1) 483 (34.3) 321 (39.5) 
  CHD 21 560 (4.4) 1171 (14.1)** 315 (12.0) ** 31 (7.6) 185 (13.1) 99 (12.2) 
  Diabetes 24 737 (5.0) 766 (9.1)** 189 (7.2)** 16 (4.0) 109 (7.7) 64 (7.9) 
  Stroke/TIA 8459 (1.7) 395 (4.7)** 98 (3.7)** 11 (2.8) 51 (3.6) 36 (4.4) 
  AF 3552 (0.7) 99 (1.2)** 34 (1.3)** 3 (0.8) 16 (1.1) 15 (1.8) 
  Heart failure 768 (0.2) 35 (0.4)** 6 (0.2) 0 1 (0.1) 5 (0.6) 
Respiratory 
  Asthma 55 245 (11.2) 3048 (36.6)** 984 (37.6)** 142 (35) 523 (37.1) 319 (39.3) 
  Pulmonary embolus 4354 (0.9) 264 (3.2)** 65 (2.5)** 12 (3.0) 32 (2.2) 21 (2.5) 
  Bronchiectasis 968 (0.2) 167 (2.0)** 39 (1.5)** 7 (1.8) 17 (1.2) 15 (1.8) 
  Pulmonary fib 504 (0.1) 67 (0.8)** 18 (0.7)** 3 (0.8) 12 (0.9) 3 (0.4) 
Cancer 37 686 (7.6) 937 (11.3) 272 (10.4) 47 (11.8) 146 (10.4) 79 (9.7) 
  Lung 405 (0.1) 52 (0.6)** 15 (0.6)** 0 7 (0.5) 8 (1.0) 
  Breast 11 311 (2.3) 210 (2.5)* 57 (2.2) 12 (3.0) 30 (2.1) 15 (1.8) 
  Prostate 3588 (0.7) 105 (1.3)** 30 (1.1)* 5 (1.3) 12 (0.9) 13 (1.6) 
  Gastrointestinal 2925 (0.6) 96 (1.2)** 34 (1.3)** 6 (1.5) 19 (1.3) 9 (1.1) 
  Haem 6170 (1.2) 124 (1.5)* 34 (1.3) 5 (1.3) 17 (1.2) 12 (1.5) 
Gastrointestinal 55 635 (11.5) 1737 (20.9)** 468 (17.9)** 76 (19.0) 254 (18.0) 138 (17.0)
  Dyspepsia 37 819 (7.7) 1257 (15.1)** 348 (13.3)** 53 (13.3) 189 (13.4) 106 (13.1) 
  Diverticular disease 5181 (1.0) 224 (2.7)** 54 (2.1)** 6 (1.5) 32 (2.3) 16 (2.0) 
  IBS 11 203 (2.3) 291 (3.5)** 64 (2.4)** 17 (4.3) 35 (2.5) 12 (1.5) 
  CLD 935 (0.2) 36 (0.4)** 10 (0.4)* 2 (0.5) 10 (0.7) 3 (0.4) 
Mental health 35 822 (7.2) 1127 (13.6)** 304 (11.6)** 54 (13.5) 162 (11.5) 88 (10.8) 
  Depression 27 578 (5.6) 901 (10.8)** 233 (8.9)** 42 (10.5) 128 (9.1) 63 (7.8) 
  Anxiety 8781 (1.8) 245 (2.9)** 69 (2.6)** 13 (3.3) 36 (2.6) 20 (2.5) 
  Schizophrenia / bipolar 1918 (0.4) 79 (0.9)** 27 (1.0)** 3 (0.7) 15 (1.1) 9 (1.1) 
Other 
  Other painful 81 733 (16.5) 2259 (27.2)** 655 (25.0)** 115 (28.8) 367 (26.0) 173 (21.3) 
  Osteoporosis 7700 (1.6) 342 (4.1)** 128 (4.9) ** 21 (5.3) 67 (4.8) 40 (4.9) 
  Connective tissue disease 10 642 (2.2) 391 (4.7)** 112 (4.3)** 19 (4.8) 72 (5.1) 21 (2.6) 
Compared with control (χ2): *P<0.05; **P<0.001.
AF, atrial fibrillation; CHD, coronary heart disease; CLD, chronic liver disease; COPD, chronic obstructive pulmonary disease; GOLD, 
Global Initiative for Chronic Obstructive Lung Disease; IBS, irritable bowel syndrome; TIA, transient ischaemic attack.
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patterns of multimorbidity and specific ADR risks 
have not been described or quantified previously.
strengths and limitations
Strengths of this study include the large sample size 
with representation from different areas of the UK. The 
range of data collected at UK Biobank assessment centres 
meant it was possible to compare a range of sociodemo-
graphic characteristics as well as spirometry data, the 
latter being unusual for a large community-based cohort. 
It is recognised, however, that UK Biobank participants 
show some evidence of ‘healthy volunteer bias’, differing 
from the UK average on a number of socioeconomic, 
lifestyle and health-related measures. Specifically they 
are less socioeconomically deprived, less likely to smoke, 
to be obese and have fewer self-reported health condi-
tions.53 All LTC diagnoses as well as medication data were 
Figure 2 Bubble plot showing percentage of participants in each comorbidity category taking ≥3 concomitant medications 
associated with specific adverse drug reactions (ADRs). The size of each bubble represents the percentage of participants 
in each comorbidity group taking ≥3 concomitant medications associated with specific ADRs according to the Scottish 
Government Polypharmacy Guideline. CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CVD, 
cardiovascular disease; GI, gastrointestinal disease; MH, mental health conditions.
Table 3 ORs (with 95% CI) for taking three of more medications associated with similar ADRs
ADR
Self-report COPD compared with no COPD
n=502 640










OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Falls 2.27 (2.13 to 2.42)*** 1.83 (1.71 to 1.96)*** 1.66 (1.47 to 1.87)*** 1.49 (1.30 to 1.69)***
Constipation 2.71 (2.54 to 2.89)*** 2.66 (2.39 to 2.96)*** 2.18 (1.77 to 2.64)*** 1.82 (1.47 to 2.24)***
Urinary retention 3.38 (2.94 to 3.87)*** 2.59 (2.22 to 3.0)*** 1.98 (1.44 to 2.64)*** 1.64 (1.18 to 2.21)**
CNS depression 3.75 (3.31 to 4.25)*** 2.81 (2.45 to 3.22)*** 2.29 (1.73 to 2.95)*** 1.87 (1.40 to 2.43)***
Bleeding 4.60 (3.35 to 6.19)*** 3.39 (2.40 to 4.66)*** 2.63 (1.25 to 4.80)** 1.76 (0.75 to 3.48)†
Renal injury 2.22 (1.86 to 2.62)*** 1.84 (1.53 to 2.19)*** 1.94 (1.41 to 2.58)*** 1.84 (1.33 to 2.49)***
Model 1: Adjusted for age, sex and socioeconomic status.
Model 2: Adjusted for age, sex, socioeconomic status, smoking, alcohol frequency, body mass index and physical activity.
**P<0.01; ***P<0.001.
†P>0.05
ADR, adverse drug reaction; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for 
Chronic Obstructive Lung Disease. 
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self-reported, with no alternative means of verification. 
We attempted to minimise this limitation by identifying a 
subset of those with COPD meeting the GOLD diagnostic 
criteria and repeating the analyses with this subset. Impor-
tantly, spirometry values were also prebronchodilator, 
which is in contravention to guidelines for diagnosing 
COPD. Additionally, information was not available about 
the strength of indication for medications and individual 
susceptibility to risk, which is a limitation when consid-
ering the risk of ADRs.
The use of the Scottish Government Polypharmacy 
Guideline allowed analysis of potential ADR risk by 
specific common ADRs. The intended purpose of this 
guideline, however, was not to identify potential risk 
from a population sample, but rather to identify poten-
tial causes of symptoms or complications. The analysis in 
this study, therefore, serves only as an approximation of 
potential risk, not an absolute marker of inappropriate 
polypharmacy. The cross-sectional nature of this anal-
ysis also precludes an analysis of actual harm as a result 
of polypharmacy. Many of the potential ADRs, such as 
falls and fractures and renal injury and frequently multi-
factorial events and may not be directly attributable to 
medication use. Despite these limitations, however, the 
co-prescription of multiple medications with similar 
ADRs strongly implies greater potential for harm. The 
association of such prescribing patterns with COPD, 
across a range of potential ADRs, is clear from our find-
ings. This analysis is, to the authors' knowledge, the first 
to attempt to quantify this risk for specific ADRs in this 
way.
Context and implications
The increased prevalence of individual LTCs such 
as coronary heart disease, hypertension, diabetes, 
dyspepsia, osteoporosis, cancer, depression and anxiety 
in those with COPD is similar to the findings from 
other population-based studies of multimorbidity in 
COPD.5 11 54–56 Our finding that cardiovascular disease 
prevalence increased with increasing severity of COPD 
is in keeping with the body of literature on cardiovas-
cular disease and COPD, in which high prevalence has 
been observed in (usually older) cohorts with severe 
airflow limitation.5 21 Greater polypharmacy with 
greater severity of COPD has also been observed previ-
ously in older COPD populations,43 57 although such 
analyses have been smaller (n=1859 and 398, respec-
tively) and have not assessed the specific patterns of 
prescribing in COPD. To the best of our knowledge, 
no previous studies have assessed the risk of ADRs as 
a result of polypharmacy in COPD. A recent popula-
tion-based analysis of prescribing data from 310 000 
adults in Scotland showed that over 15 years from 1995 
to 2010 the proportion of people with polypharmacy 
and with potentially serious drug-to-drug interactions 
increased dramatically.37 The number of prescribed 
medications was also associated with increased risk of 
interactions. Our analysis differs in approach from this 
analysis, by seeking to identify patterns of prescribing 
increasing risk of specific adverse events, rather than 
counting total potential interactions. The strength of 
our approach lies in highlighting specific patterns of 
multimorbidity in which specific ADRs are more likely. 
Our findings can therefore be applied to clinical prac-
tice, highlighting the importance of recognising multi-
morbidity in COPD and being alert to specific ADRs 
when prescribing medication.
Our findings indicate that in those with COPD the 
potential for ADRs as a result of combinations of medi-
cations is high and this appears to be the result of a high 
prevalence of extra-pulmonary LTCs. Clinical guide-
lines for COPD should place greater emphasis on the 
need for assessment of associated multimorbidity and 
the risk of associated ADRs. While our analysis shows 
potential areas where ADR risk exists in COPD (eg, falls 
or renal injury in those with concomitant cardiovas-
cular disease, CNS depression, bleeding or constipation 
with concomitant mental health conditions), future 
research is merited to assess what actual harm could be 
attributed to such prescribing patterns.
COnClusiOn
Among UK Biobank participants with COPD, there 
was considerable multimorbidity and polypharmacy. 
Those with COPD were highly likely to be concurrently 
prescribed multiple medications with similar potential 
adverse effects. Medications contributing to this risk 
were largely indicated for the management of the asso-
ciated morbidities rather than COPD. Future research 
should examine the effects on healthcare outcomes of 
co-prescribing of multiple drugs with similar potential 
of ADRs. Clinical guidelines for COPD should empha-
sise the need for assessment of multimorbidity and the 
risk of associated ADRs.
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